Express Delivery of Next-Generation CAR T Cells with Preserved Naive and Stemness Phenotypes for the Treatment of Aggressive Lymphomas
Related Experiment Video
Updated: Jul 17, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1The University of Texas MD Anderson Cancer Center, Houston, Texas.
Summary:
In this issue of Cancer Discovery, Dickinson and colleagues present clinical data from a first-in-human study of YTB323, a novel autologous CD19-directed chimeric antigen receptor T-cell therapy generated on the T-Charge platform with preserved naive state and stemness phenotypes. Treatment with YTB323 achieved high overall response rates, durable complete remissions, and good overall safety. Their cell doses are up to 25-fold lower than with tisagenlecleucel. See related article by Dickinson et al., p. 1982 (10).
Insights
A new CAR T-cell therapy, YTB323, shows high response rates and durable remissions in early trials. This therapy uses the T-Charge platform and requires significantly lower cell doses compared to existing treatments.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Chimeric antigen receptor (CAR) T-cell therapy has revolutionized cancer treatment.
- Existing CAR T-cell therapies can be associated with high cell doses and potential toxicities.
- The T-Charge platform aims to improve CAR T-cell therapy by preserving T-cell stemness phenotypes.
